PIK3CA and breast cancer: Subsequently, a PIK3CA mutation-driven immune signature (PDIS) was developed based on TCGA data, and we validated its capacity for BC patient risk stratification using the Gene Expression Omnibus database (GEO, https://www.ncbi.nlm.nih.gov/geo/).